Liver lesions are areas of abnormal tissue within the liver, and they are far more common than most people realize. Roughly one in six hospital patients undergoing abdominal ultrasound turns out to have at least one focal liver finding, and the vast majority of those findings are harmless. The challenge is that the same imaging tools that catch benign cysts also flag growths that could be cancerous, and the gap between “definitely fine” and “needs treatment” is where modern hepatology earns its keep.
How Common Are Liver Lesions, and Why Are More Being Found?
Advances in imaging technology and the expansion of routine health screenings have pushed detection rates upward over the past two decades. Cross-sectional scans ordered for unrelated complaints now regularly reveal liver findings that would have gone unnoticed a generation ago.1PubMed Central. Characterization of incidental liver lesions: comparison of multidetector CT versus Gd-EOB-DTPA-enhanced MR imaging A large ultrasound study of more than 45,000 hospital patients found a focal liver lesion in about 15% of them. The most frequent finding was focal fatty sparing (about 6.3%), followed closely by simple cysts (about 5.8%) and hemangiomas (roughly 3.3%). Focal nodular hyperplasia showed up in about 0.2% of patients, and hepatic adenomas were rare at around 0.04%.2PubMed Central. Prevalence of benign focal liver lesions: ultrasound investigation of 45,319 hospital patients
In practical terms, if you have an abdominal CT or ultrasound for a kidney stone, gallbladder pain, or even a car accident, there is a reasonable chance the radiologist will mention something in the liver. For most people, that incidental dot is a cyst or a hemangioma that will never cause symptoms. But understanding what drives the different types of lesions, and how clinicians tell them apart, matters enormously for the subset that does require action.
What Causes Benign Liver Lesions
Benign lesions form through several distinct mechanisms, and lumping them together as “nothing to worry about” glosses over real biological differences.
Hemangiomas are the most common solid benign liver tumor. They are essentially tangles of blood vessels lined with normal endothelial cells. They grow slowly, rarely cause symptoms, and almost never rupture unless they become very large. Most are discovered incidentally and require nothing more than a note in your medical record.
Focal nodular hyperplasia (FNH) has a more interesting origin. It is thought to be a hyperplastic response to abnormal blood flow from a pre-existing vascular malformation within the liver.3PubMed. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma In other words, the liver cells around an oddly formed artery grow faster than normal because they receive extra blood supply. FNH is not cancerous, does not tend to bleed, and almost never needs to be removed. It is far more common in women of reproductive age, though the reasons for that skew remain debated.
Hepatic adenomas sit in a less reassuring category. They are true benign tumors of liver cells, and they carry real risks. In one large molecular study, symptomatic bleeding occurred in about 14% of patients with adenomas, and roughly 3% of patients went on to develop liver cancer arising from the adenoma.4PubMed. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation Molecular profiling has identified at least eight subtypes, each driven by different genetic events. Some subtypes are linked to hormone imbalances from oral contraceptive use, while others are associated with obesity. Certain subtypes carrying specific mutations are more prone to bleeding, and others have a higher risk of transforming into cancer. This molecular complexity is why many guidelines recommend removing adenomas above a certain size, particularly in men, where the malignant transformation risk is higher.
Simple hepatic cysts are fluid-filled sacs lined with bile duct cells. A solitary cyst is extremely common and almost always benign. Polycystic liver disease is a different matter altogether. The European Association for the Study of the Liver defines polycystic liver disease as ten or more cysts within the liver not connected to the bile duct system.5Kosin Medical Journal. Polycystic liver disease: an overview of clinical manifestations, diagnosis, and treatment In severe cases, the liver can become massively enlarged, causing abdominal pain, early satiety, and pressure on nearby organs. Treatment options range from cyst aspiration and sclerotherapy to, in extreme situations, liver transplantation.
How Malignant Liver Lesions Develop
The two primary liver cancers, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), arise through different pathways, and the liver is also one of the most common destinations for cancers that start elsewhere.
Hepatocellular Carcinoma and Chronic Inflammation
HCC accounts for the majority of primary liver cancers and almost always develops in a liver that has been damaged for years. Chronic hepatitis B or C infection, heavy alcohol use, and metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) are the leading drivers. What these causes share is a cycle of liver-cell death, inflammation, and regeneration that eventually creates conditions ripe for cancerous mutations.
In the case of MASH, the process begins with fat accumulation. Saturated fatty acids disrupt the internal machinery of liver cells, stressing the endoplasmic reticulum (a protein-folding workshop inside the cell) and overloading the mitochondria (the cell’s energy factories). This produces a surplus of reactive oxygen species that damage DNA and trigger various forms of cell death.6JHEP Reports. Inflammation in MASLD progression and cancer Dying liver cells release distress signals that activate resident immune cells called Kupffer cells, which in turn pump out inflammatory molecules like TNF-alpha and interleukin-6. These inflammatory signals recruit more immune cells, fueling a self-perpetuating loop of damage and repair.7PubMed Central. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives Over years, this chronic inflammation drives scarring (fibrosis), and the resulting environment of constant cell turnover and DNA damage raises the odds that a liver cell will acquire the right combination of mutations to become cancerous.
Cholangiocarcinoma
ICC arises from the bile duct cells inside the liver. It is rarer than HCC but typically more difficult to treat because it is often found at a more advanced stage. The molecular landscape of ICC is diverse. Research analyzing driver mutations has shown that the cancer can be grouped into distinct genomic clusters, each with different mutation profiles and different microscopic appearances. Some clusters tend to form tumors resembling large bile ducts, while others look more like small ductular structures.8Theranostics. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities These molecular differences matter because they may predict which targeted therapies a patient’s tumor will respond to.
Metastatic Liver Lesions
The liver’s enormous blood supply makes it a prime landing site for cancer cells shed from tumors elsewhere, particularly colorectal cancer but also breast, lung, and pancreatic cancers. In colorectal cancer, tumor cells can reach the liver via the portal vein (the blood vessel that drains the intestines directly into the liver) or through peritoneal spread. The route a tumor takes depends on factors in the tumor’s microenvironment, immunological markers, and specific adhesion molecules on the cancer cells.9Hindawi / Journal of Oncology. Mechanisms of Metastasis in Colorectal Cancer and Metastatic Organotropism: Hematogenous versus Peritoneal Spread Distinguishing a metastasis from a primary liver cancer is critical because the treatment strategy is completely different.
How Imaging Tells Lesions Apart
Modern imaging does not just detect a lump; it characterizes the lump’s blood-flow behavior, cellular composition, and contrast-uptake patterns to narrow down what it might be. Three main modalities carry most of the diagnostic weight.
CT and MRI
Multiphase contrast-enhanced CT is widely available and fast, making it the workhorse for initial evaluation. But MRI using liver-specific contrast agents consistently outperforms CT in head-to-head comparisons. In one multicenter study, MRI with a liver-specific gadolinium agent achieved a sensitivity of about 83% for detecting HCC, compared with 70% for CT.10PubMed. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study Another study found MRI sensitivity around 87% and specificity around 94%, versus roughly 66% and 79% for CT.11PubMed. Detection and classification of different liver lesions: comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation A more recent investigation reported similar trends, with MRI reaching 90% sensitivity and 87% specificity compared with 85% and 80% for CT.12Biomedical Sciences and Clinical Medicine. Comparison of Contrast-Enhanced MRI Using Hepatocyte-Specific Contrast with Contrast-Enhanced CT in Evaluation of Hepatobiliary Space-Occupying Lesions
The MRI advantage comes largely from its hepatobiliary phase, where liver-specific contrast is taken up by functioning liver cells but not by most tumors. This creates a sharp visual contrast between normal liver and suspicious tissue. HCC, for example, typically appears bright in the arterial phase (because it gets its blood supply from the hepatic artery) and then washes out and turns dark in later phases. That pattern is so characteristic that, in the right clinical context, it can be used to diagnose HCC without a biopsy.
Contrast-Enhanced Ultrasound
Contrast-enhanced ultrasound (CEUS) uses microbubble contrast agents injected into a vein, allowing real-time observation of how blood flows into and out of a lesion. It carries no radiation and poses no kidney toxicity risk, making it a good option for patients who cannot undergo CT or MRI.13PubMed Central. Contrast-enhanced ultrasound approach to the diagnosis of focal liver lesions: the importance of washout The critical feature on CEUS is “washout,” meaning the lesion loses its contrast enhancement faster than the surrounding liver. Washout is highly suggestive of malignancy, and its timing and intensity can help distinguish HCC from other cancers. One software-based perfusion study showed that metastases from colorectal and pancreatic cancers exhibited rapid, pronounced washout compared to HCC, which washed out more slowly.14PubMed. Differentiation of malignant liver tumors by software-based perfusion quantification with dynamic contrast-enhanced ultrasound (DCEUS) A systematic review and meta-analysis confirmed that quantitative CEUS parameters can reliably differentiate HCC from intrahepatic cholangiocarcinoma using measures like rise time and wash-out characteristics.15PubMed Central. Dynamic contrast enhanced ultrasound in differential diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis
Standardized Reporting With LI-RADS
To reduce ambiguity, the Liver Imaging Reporting and Data System (LI-RADS) standardizes how radiologists interpret and report imaging findings in patients at risk for HCC.16PubMed Central. LI-RADS v2017 for liver nodules: how we read and report Each observation is assigned a category from LR-1 (definitely benign) to LR-5 (definitely HCC), with intermediate categories for lesions that show some but not all hallmarks of cancer. This shared language means a hepatologist in one city can read a LI-RADS report from another institution and immediately understand the level of concern.
Blood-Based Detection and Tissue Sampling
Imaging is the backbone of liver-lesion diagnosis, but blood tests and biopsies fill important gaps.
Alpha-fetoprotein (AFP) has long been the standard blood marker for HCC, though it is far from perfect since many early tumors produce little or no AFP. Newer approaches collectively called liquid biopsy aim to capture tumor signals circulating in the bloodstream, including tumor DNA fragments and whole tumor cells. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) show promise for early detection and for monitoring recurrence after treatment.17PubMed Central. Liquid biopsy for early detection of hepatocellular carcinoma In one study of patients who had undergone curative liver surgery, the presence of a specific type of circulating tumor cell roughly doubled the risk of early recurrence, and combining that marker with high AFP levels further improved the ability to identify patients headed for relapse.18Scientific Reports. EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
Percutaneous liver biopsy remains necessary when imaging cannot clearly characterize a lesion. A study of more than 900 biopsies found a diagnostic yield above 92% regardless of whether a coaxial or non-coaxial needle technique was used. Major complications like significant bleeding were uncommon, occurring in about 1.2% of procedures. Tumor seeding along the needle track, a longstanding worry, was also rare and was lower with the coaxial technique (about 1.3% versus 3.1%).19PubMed Central. Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk
Surveillance in High-Risk Patients
For people with cirrhosis or chronic hepatitis B, regular screening aims to catch HCC at a stage where curative treatment is still possible. International guidelines recommend ultrasound every six months. A meta-analysis found that surveillance ultrasound detected the majority of tumors before they caused symptoms, with an overall pooled sensitivity around 94%. However, for early-stage HCC specifically (the tumors small enough to be cured), sensitivity dropped to about 63%.20PubMed Central. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis That same meta-regression analysis showed that screening every six months was significantly more sensitive for early HCC than annual screening. The practical implication is clear: sticking to the six-month interval matters. Separate data suggests that about 40% of nodules smaller than 2 cm escape detection by ultrasound altogether, underlining the need for better screening tools in patients with coarse, cirrhotic livers.21PubMed Central. Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns
Treatment Approaches and Their Trade-Offs
The right treatment for a malignant liver lesion depends on the type of cancer, how much liver is involved, and how well the remaining liver functions. In cirrhotic patients, the liver’s reserve capacity is the limiting factor. Guidelines traditionally restrict curative surgical resection to patients with well-compensated cirrhosis and no significant portal hypertension, though improvements in surgical technique and perioperative care have expanded the pool of operable patients somewhat.22PubMed Central. Liver surgery in cirrhosis and portal hypertension
For tumors that cannot be surgically removed, locoregional therapies offer alternatives. Radiofrequency ablation (RFA) uses heat delivered through a needle to destroy tumor tissue, while transarterial chemoembolization (TACE) injects chemotherapy drugs directly into the artery feeding the tumor and then blocks that artery to trap the drugs in place. For larger solitary HCCs, both approaches produce comparable long-term survival, though RFA tends to achieve better initial tumor control.23PubMed Central. Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm Combining the two techniques appears to improve outcomes further. A meta-analysis found that pairing TACE with thermal ablation (either RFA or microwave ablation) roughly halved the risk of death and of tumor progression compared with TACE alone, without significantly increasing major complications.24PubMed. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis
Immunotherapy has changed the landscape for advanced HCC. In the IMbrave150 trial and a separate multicenter cohort, patients who achieved a complete response to immunotherapy had remarkable outcomes: their median progression-free survival and overall survival had not been reached even after follow-up periods of two years or more.25JAMA Network Open. Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma Complete responses remain the exception rather than the rule, but these results underscore how profoundly the treatment calculus has shifted for patients who respond.
Liver transplantation offers the best long-term outcomes for early-stage HCC because it removes both the tumor and the diseased liver that gave rise to it. Under the traditional Milan criteria, five-year post-transplant survival reaches about 79%. A large, long-term study found that patients who exceeded Milan but still met the slightly broader UCSF criteria had a five-year survival around 64%, a difference that was not statistically significant. Patients with tumors beyond even the UCSF criteria, however, saw survival drop below 50% at five years.26PubMed Central. Liver Transplantation Criteria For Hepatocellular Carcinoma Should Be Expanded: A 22-Year Experience With 467 Patients at UCLA This data has fueled ongoing debate about whether transplant eligibility criteria should be expanded modestly, particularly as better bridging therapies become available to control tumors while patients wait for donor organs.
Artificial Intelligence in Liver Lesion Diagnosis
AI tools for reading liver images have moved from academic curiosities into multicenter validation. One system tested on CT scans from more than 4,000 patients across six centers achieved about 95% accuracy and a 97% area under the curve for distinguishing benign from malignant tumors.27Nature Communications. Focal liver lesion diagnosis with deep learning and multistage CT imaging Another large-scale AI system, when applied to routine clinical ultrasound, matched or exceeded senior radiologists’ performance for malignant lesion detection and, in a triage study of over 13,000 consecutive patients, automatically classified more than three quarters as low risk with a negative predictive value of 99%.28Nature Communications. A multicenter clinical AI system study for detection and diagnosis of focal liver lesions
On the MRI side, a deep learning model trained on multiparametric MRI improved the diagnostic accuracy of less experienced radiologists by an average of about 5 percentage points and cut their reading time by roughly 35 seconds per case.29PubMed. An Explainable Deep Learning Model for Focal Liver Lesion Diagnosis Using Multiparametric MRI The practical appeal is less about replacing radiologists than about leveling the playing field: AI assistance brings a junior reader’s performance close to that of an expert, which matters in hospitals that lack subspecialty liver-imaging expertise. These systems are still being refined and validated, but the consistency of results across multiple centers and imaging modalities suggests they will become standard clinical tools in the near future.
Liver Lesions in Children
The spectrum of liver lesions in children looks quite different from that in adults. Infantile hemangiomas and mesenchymal hamartomas are common benign findings in the first two years of life. On the malignant side, hepatoblastoma is the most frequent primary liver cancer in young children, and it is biologically distinct from the hepatocellular carcinoma seen in adults. Complete surgical resection remains the cornerstone of curative treatment for hepatoblastoma.30PubMed Central. Differential diagnosis and management of liver tumors in infants The good news is that hepatoblastoma is highly chemosensitive, and survival rates have improved dramatically with neoadjuvant chemotherapy that can shrink tumors before surgery. Parents confronted with a liver mass in their child should know that the diagnosis, treatment pathway, and prognosis differ substantially from the adult disease, and referral to a pediatric hepatobiliary center is essential.